Recentin (cediranib) - AstraZeneca
Lynparza (olaparib) - Merck (MSD), AstraZeneca
Lynparza + cediranib: Acceptance of regulatory submission in US for recurrent platinum-resistant ovarian cancer (based on CONCERTO trial) in H2 2020 (AstraZeneca) - Mar 22, 2020 - Annual Report 2019 
sNDA
https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-report-2019/pdf/AstraZeneca_AR_2019.pdf
 
Mar 22, 2020
 
 
a301d769-f47f-4aec-9451-756e14955711.jpg